Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non-Current Liabilities: 2021-2022

Historic Other Non-Current Liabilities for Foghorn Therapeutics (FHTX) over the last 2 years, with Dec 2022 value amounting to $29,000.

  • Foghorn Therapeutics' Other Non-Current Liabilities was N/A to $656,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $656,000, marking a year-over-year change of. This contributed to the annual value of $29,000 for FY2022, which is 79.72% down from last year.
  • According to the latest figures from FY2022, Foghorn Therapeutics' Other Non-Current Liabilities is $29,000, which was down 79.72% from $143,000 recorded in FY2021.
  • In the past 5 years, Foghorn Therapeutics' Other Non-Current Liabilities registered a high of $143,000 during FY2021, and its lowest value of $29,000 during FY2022.
  • Over the past 2 years, Foghorn Therapeutics' median Other Non-Current Liabilities value was $86,000 (recorded in 2021), while the average stood at $86,000.
  • Data for Foghorn Therapeutics' Other Non-Current Liabilities shows a maximum YoY crashed of 79.72% (in 2022) over the last 5 years.
  • Yearly analysis of 2 years shows Foghorn Therapeutics' Other Non-Current Liabilities stood at $143,000 in 2021, then slumped by 79.72% to $29,000 in 2022.